Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.
Anil Koul’s life and career journey, from Srinagar in India where he was born, all the way to the lab of renowned cancer biologist Alex Ullrich at the Max Planck Institute in Germany and then on to Johnson & Johnson and India’s Council of Scientific And Industrial Research (CSIR), where he worked with some of the sharpest scientific minds, is one of hard work, grit and destiny.
It was philosophy that the young Koul was drawn to initially with he and a friend devouring several relevant books...
The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.
The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.
Series B cash will be used to advance its Stargardt disease gene therapy.
